Novel therapeutic approaches for small cell lung cancer (SCLC) using CRISPR-based methods
Official title: Novel therapeutic development for small cell lung cancer
Funded at Sloan-Kettering Inst Can Research · NIH-11378420 · Data updated 2026-11-12
Aimed at developing new treatments for small cell lung cancer by using CRISPR-based approaches to target diverse tumor cells and improve therapies.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | August 10, 2021 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $1,062,000 |
| NIH project number | 5R35CA263816-06 |
| Project ID | NIH-11378420 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with small cell lung cancer who consent to provide tumor samples and participate in future translational studies or trials may be eligible.
✕Less likely to help
Patients with SCLC who are not eligible for sample collection or future trials may not directly benefit.
What this research studies
This grant focuses on advancing small cell lung cancer research through a CRISPR-based platform to understand tumor heterogeneity, stem-like cell populations, and macrophage subtypes within patient tumors. Researchers will build on two decades of SCLC study, translating laboratory findings into clinical testing and analyzing patient biospecimens to guide future directions. The work integrates basic discovery with clinical translation to identify precise gene targets and CRISPR strategies that could enhance treatment options for people with SCLC.
Why it matters
Potential benefit: If successful, this work could lead to smarter, more effective CRISPR-based therapies for SCLC and better-informed clinical trials.
How similar studies have gone: Prior studies have shown that CRISPR and related genome-editing approaches can reveal actionable targets and inform therapy in cancer models, suggesting potential for translation in SCLC.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Rudin, Charles M. — Sloan-Kettering Inst Can Research
- Study coordinator: Rudin, Charles M.
Related research
Other NIH-funded projects on the same topics.
-
ABL kinase signaling and DNA collisions in small cell lung cancer
A drug target study in small cell lung cancer explores how blocking ABL kinase affects conflicts between transcription and DNA replication, which could influence tumor growth and survival.
-
XRN1 as a potential therapy target in lung cancer
A scientist-led program will study a cellular gene called XRN1 to see if turning it off can help treat non-small cell lung cancer.
-
Intermittent fasting with PD-1 inhibitors for non-small cell lung cancer
This grant tests whether a fasting-mimicking diet can boost the effectiveness of PD-1 inhibitors for people with non-small cell lung cancer.
-
Targeting STRAP to curb NSCLC spread with nanoparticle therapy
Aimed at non-small cell lung cancer, this grant tests how blocking a protein called STRAP with nanoparticles could slow cancer spread and make chemotherapy work better.
-
Modeling tumor differences to guide new treatments for resistant small cell lung cancer
A study aims to understand why some small cell lung cancer tumors resist treatment and use those insights to develop new targeted therapies.
-
TP53-mutant NSCLC: how epigenetic viral mimicry could boost immune therapy
A research grant exploring how p53 mutations in non-small cell lung cancer affect responses to a viral mimicry-based epigenetic therapy, with the goal of improving immune therapy outcomes for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.